A previous study showed that a low ccf-mtDNA content was associated with an increased risk for developing HBV-HCC (Li et al., 2016), while the current study suggested that the high level of ccf-mtDNA was associated with the poor outcome of HBV-HCC patients receiving TACE combined with TCM. This evidence concerns the gene PITX1 and hepatocellular carcinoma.